Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity - GBI Research Reports

Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity

Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity - GBI Research Reports
Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity
Published Sep 01, 2011
153 pages — Published Sep 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research has released its latest research, Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity which provides insights into the licensing agreements of large pharmaceutical companies. The report provides an in-depth analysis of the major licensing agreement trends in the pharmaceutical industry along with product and technology licensing trends. In addition, the report also analyzes the top 20 pharmaceutical companies with respect to the licensing agreement activities.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts.

Scope

The scope of this report includes -
- Major market trends that are expected to shape the licensing and deal making landscape in pharmaceutical industry
- Trends in deals for product licensing and technology licensing agreements.
- Extensive research and analysis of the licensing activity of large pharmaceutical companies.
- Licensing and deal making segmentation of top 20 in the pharmaceutical companies by phase, type, geography and value
- Company profiles of leading biotech companies active in licensing and deal making

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the pharmaceutical industry.
- Enable better product lifecycle management by identifying key phases of product licensing agreements.
- Develop segment specific strategies for licensing and deal making in pharmaceutical industry.
- Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading pharma companies.
- Accelerate and strengthen your market position by identifying key companies for licensing agreements.

  
Source:
Document ID
GBIHC107MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents310
  List of Tables71
  List of Figures85
Licensing Strategies In Large Pharmaceutical Companies Introduction133
  Licensing Agreement An Authorization132
  GBI Research Report Guidance151
Trends in In-licensing and Out-licensing Agreements162
  In-Licensing Compensates For Declining Internal R&D161
  Licensing Key To Combat Patent Cliff161
  Spiraling Cost of Licensing Deals161
    Competition to Restock Pipelines161
    Biotechs Push Products through Further Stages of Development162
Product Licensing182
  Licensing Offsets Deficiencies in Internal Pipelines and Portfolios181
  Oncology Therapy Area Spearheads Licensing Agreements in Big Pharma Companies181
  Licensing Deals in Asia-Pacific on the Rise191
Technology Licensing Deals201
  Importance of Technology In-Licensing201
  Technology Licensing With Universities201
Major Licensing Deals of Big Pharma Companies 2010213
  High Value Deals of Big Pharma Players 2010211
    GlaxoSmithKline Enters Into Licensing Agreement with Isis Pharmaceuticals211
      Overview211
      Deal Rationale221
    Sanofi-Aventis enters Into Licensing Agreement with Avila Therapeutics221
      Overview221
      Deal Rationale221
    Boehringer Ingelheim Enters into Licensing Agreement With f-star Biotechnologische221
      Overview221
      Deal Rationale221
    Merck Amends Its Collaboration Agreement with Ariad Pharmaceuticals231
      Overview231
      Deal Rationale231
    AstraZeneca Enters Into Licensing Agreement with Rigel Pharmaceuticals231
      Overview231
      Deal Rationale231
Licensing Strategies of Major Pharma Companies24125
  GlaxoSmithKline241
    Overview241
    Licensing Agreements GSK241
    By Value252
    By Type271
    By Geography281
    By Therapy Area291
    By Phase301
  J&J311
    Overview311
    Licensing Agreements J&J311
    By Value322
    By Type341
    By Geography351
    By Therapy Area361
    By Phase371
  Roche381
    Overview381
    Licensing Agreements Roche381
    By Value392
    By Type411
    By Geography421
    By Therapy Area431
    By Phase441
  Abbott451
    Overview451
    Licensing Agreements Abbott451
    By Value461
    By Type471
    By Geography481
    By Therapy Area491
    By Phase501
  Eli Lilly511
    Overview511
    Licensing Agreements Eli Lilly511
    By Value522
    By Type541
    By Geography551
    By Therapy Area561
    By Phase571
  Novartis581
    Overview581
    Licensing Agreements Novartis581
    By Value592
    By Type611
    By Geography621
    By Therapy Area631
    By Phase641
  Sanofi651
    Overview651
    Licensing Agreements Sanofi651
    By Value662
    By Type681
    By Geography691
    By Therapy Area701
    By Phase711
  Takeda721
    Overview721
    Licensing Agreements Takeda722
    By Value741
    By Type751
    By Geography751
    By Therapy Area761
    By Phase771
  Pfizer781
    Overview781
    Licensing Agreements Pfizer781
    By Value792
    By Type811
    By Geography821
    By Therapy Area831
    By Phase841
  Bristol-Myers Squibb851
    Overview851
    Licensing Agreements Bristol-Myers Squibb851
    By Value862
    By Type881
    By Geography891
    By Therapy Area901
    By Phase911
  Boehringer-Ingelheim921
    Overview921
    Licensing Agreements Boehringer Ingelheim921
    By Value931
  Merck &Co.941
    Overview941
    Licensing Agreements Merck &Co.941
    By Value952
    By Type971
    By Geography981
    By Therapy Area991
    By Phase1001
  Bayer1011
    Overview1011
    Licensing Agreements Bayer1011
    By Value1022
    By Type1041
    By Geography1051
    By Therapy Area1061
    By Phase1071
  AstraZeneca1081
    Overview1081
    Licensing Agreements AstraZeneca1081
    By Value1092
    By Type1111
    By Geography1121
    By Therapy Area1131
    By Phase1141
  Astellas1151
    Overview1151
    Licensing Agreements Astellas1151
    By Value1162
    By Type1181
    By Geography1191
    By Therapy Area1201
    By Phase1211
  Daiichi-Sankyo1221
    Overview1221
    Licensing Agreements Daiichi Sankyo1221
    By Value1231
    By Type1241
    By Geography1251
    By Therapy Area1261
    By Phase1271
  Teva Pharma1281
    Overview1281
    Licensing Agreements Teva1281
    By Value1293
    By Geography1321
    By Therapy Area1321
    By Phase1331
  Eisai1341
    Overview1341
    Licensing Agreements Eisai1341
    By Value1351
    By Type1361
    By Geography1371
    By Therapy Area1381
    By Phase1391
  Baxter1401
    Overview1401
    Licensing Agreements Baxter1401
    By Value1411
    By Type1421
    By Therapy Area1431
  Amgen1441
    Overview1441
    Licensing Agreements Amgen1441
    By Value1451
    By Geography1461
    By Therapy Area1471
    By Phase1481
Licensing Strategies In Large Pharmaceutical Companies Appendix1495
  Market Definitions1491
  Abbreviations1491
  Research Methodology1493
    Coverage1501
    Secondary Research1501
    Primary Research1501
    Expert Panel Validation1511
  Section Wise Methodology1512
    Trends in In-licensing and Out-licensing Agreements1511
    Product Licensing1511
    Technology Licensing Deals1511
    Major Licensing Deals of Big Pharma Companies 20101521
    Licensing Strategies of Major Pharmaceutical Companies1521
  Contact Us1521
  Disclaimer1521
  Sources1531

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity" Sep 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Licensing-Strategies-of-Large-Pharmaceutical-Companies-Weak-R-D-Pipelines-and-the-Patent-Cliff-Stimulate-In-Licensing-Activity-2115-245>
  
APA:
GBI Research Reports. (2011). Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity Sep 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Licensing-Strategies-of-Large-Pharmaceutical-Companies-Weak-R-D-Pipelines-and-the-Patent-Cliff-Stimulate-In-Licensing-Activity-2115-245>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.